The Effect of Serum Procalcitonin on Distinguishing the Main Pathogens of Bloodstream Infection
XUE Hai-ling,ZENG Zhao-wei,SUN Lan-ju
Department of Clinical Laboratory, Tianjin Nankai Hospital, Tianjin 300100, China
Abstract:
Objective To explore the role of serum procalcitonin(PCT) in distinguishing different types of pathogens of bloodstream infections, so as to provide guidance for early clinical selection of antibacterial drugs. Methods The clinical data of 274 patients with positive blood culture (single bacteria) from November 2017 to December 2019 were collected.The serum PCT levels were detected and the different levels of PCT from three groups including gram-positive(G-) bacteria, gram-negtive (G+)bacteria and fungi groups as well as different pathogens were analyzed. Results Among the 274 blood culture positive specimens, 142 cases [52.01% (142/274)] were Gbacteria, 87 cases[31.50% (87/274)] were G+ bacterial infection, and 45 cases[16.48% (45/274)] were fungi infection. There were statistical significance in the difference of PCT levels among the G-bacterium group, the G+ bacteria group and the fungi group (H=43.722, P<0.05). The total PCT positive rate of the 274 patients with bloodstream infection was 71.53% (196/274).There were statistical significance in the difference of PCT positive rate among the Gbacterium group, the G+ bacteria group and the fungi group(χ2 =19.098, P<0.05). There were statistical significance in the difference of PCT grouping among G-bacterium group, G+ bacteria group and fungi group (χ2 =33.404, P<0.05). Among the G-bacteria, the PCT detection level and positive rate of Klebsiella pneumoniae was significantly higher campared to Acinetobacter baumannii(P<0.05). The PCT positive rate of Pseudomonas aeruginosa was significantly higher compared to Acinetobacter baumannii (P<0.05). Conclusion Serum PCT detection has certain hints in distinguishing different types of pathogens of bloodstream infections. Serum PCT detection combined with blood culture can provide a basis for the rational selection of antibacterial drugs in the early clinical stage.
